Therefore, the authors proposed that downregulation of NRF2 and AKR1C1 through Brusatol or Metformin administration might be useful to overcome progestin therapy failure in patients with endometrial cancer that require a more conservative approach [358] (see Table 2). Here, NFE2L2 is linked to endometrial cancer.